Characteristics of Ankylosing Spondylitis Associated Uveitis

Sponsor
Benha University
Study ID
NCT07113834
Status
Completed

Conditions

  • Uveitis

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — DRUG
    A tumor necrosis factor-alpha (TNF-α) inhibitor used as a biologic agent for the treatment of ankylosing spondylitis. Administered subcutaneously as part of systemic immunomodulatory therapy.
  • Systemic corticosteroids — DRUG
    Oral or intravenous corticosteroids (e.g., prednisolone) used to suppress systemic inflammation in cases of active AS or severe uveitis.

Study Details

This study aims to understand the clinical characteristics associated with AAU in Egyptian AS patients, and the prognostic factors, in terms of the Corrected Distance Visual Acuity (CDVA).

Key Dates

First listed
Aug 11, 2025
Start date
Sep 1, 2023
Status verified
Sep 2023
Primary completion
Sep 1, 2023
Completion
Aug 1, 2024

Study Design

Enrollment
22 participants (actual)

Primary Outcome Measure

Change in Corrected Distance Visual Acuity (CDVA) [ Time Frame: Baseline and 3-month follow-up ]

Related Studies